Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioXcel Therapeutics Q4 GAAP EPS $(0.76) Beats $(0.91) Estimate, Sales $376.00K Miss $710.00K Estimate

Author: Benzinga Newsdesk | March 12, 2024 07:03am
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.91) by 16.48 percent. This is a 61.03 percent increase over losses of $(1.95) per share from the same period last year. The company reported quarterly sales of $376.00 thousand which missed the analyst consensus estimate of $710.00 thousand by 47.04 percent. This is a 57.98 percent increase over sales of $238.00 thousand the same period last year.

Posted In: BTAI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist